Ocugen, Inc. (OCGN)
- Previous Close
1.1800 - Open
1.1500 - Bid 1.1900 x 600
- Ask 1.2000 x 300
- Day's Range
1.1100 - 1.2400 - 52 Week Range
0.3450 - 2.1050 - Volume
4,114,962 - Avg. Volume
9,302,756 - Market Cap (intraday)
306.217M - Beta (5Y Monthly) 3.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date May 3, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.67
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
www.ocugen.comRecent News: OCGN
Performance Overview: OCGN
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCGN
Valuation Measures
Market Cap
303.64M
Enterprise Value
271.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.76
Price/Book (mrq)
7.49
Enterprise Value/Revenue
44.92
Enterprise Value/EBITDA
-4.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.30%
Return on Equity (ttm)
-110.14%
Revenue (ttm)
6.04M
Net Income Avi to Common (ttm)
-63.08M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
39.46M
Total Debt/Equity (mrq)
17.11%
Levered Free Cash Flow (ttm)
-48.98M